[go: up one dir, main page]

WO2024243553A2 - Système auto-injecteur - Google Patents

Système auto-injecteur Download PDF

Info

Publication number
WO2024243553A2
WO2024243553A2 PCT/US2024/031099 US2024031099W WO2024243553A2 WO 2024243553 A2 WO2024243553 A2 WO 2024243553A2 US 2024031099 W US2024031099 W US 2024031099W WO 2024243553 A2 WO2024243553 A2 WO 2024243553A2
Authority
WO
WIPO (PCT)
Prior art keywords
chamber
auto
injector
reconstitution
liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/031099
Other languages
English (en)
Other versions
WO2024243553A3 (fr
Inventor
Girum Yemane-Tekeste
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meridian Medical Technologies LLC
Original Assignee
Meridian Medical Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meridian Medical Technologies LLC filed Critical Meridian Medical Technologies LLC
Publication of WO2024243553A2 publication Critical patent/WO2024243553A2/fr
Publication of WO2024243553A3 publication Critical patent/WO2024243553A3/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A61M5/2033—Spring-loaded one-shot injectors with or without automatic needle insertion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A61M5/2066—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically comprising means for injection of two or more media, e.g. by mixing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A61M2005/2006—Having specific accessories
    • A61M2005/2013—Having specific accessories triggering of discharging means by contact of injector with patient body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A61M2005/206—With automatic needle insertion

Definitions

  • Lyophilized drugs and vaccines are commercially limited because of the complexity of reconstituting the drug into a useable form.
  • a lyophilized drug is reconstituted from a vial using equipment and a number of steps. Once reconstituted, the drug is delivered to a patient through, e.g., intravascular infusion, or intravascular, intramuscular, or subcutaneous injection.
  • Exemplary embodiments of the systems (e.g., reconstitution auto-injectors) and methods (e.g., of using reconstitution auto-injectors) described herein are designed to reconstitute a drug and administer it automatically (e.g., to a patient).
  • the system stores a powder material, such as a drug (e.g., lyophilized drug) and its diluent in two separate chambers.
  • a drug e.g., lyophilized drug
  • the system and methods are configured to reconstitute the drug by automatically mixing the diluent with the powder, and thereafter inject the reconstituted material into a recipient.
  • a drug is understood to include a material used for the health of a person.
  • a drug may include a medication for responding to illnesses and/or symptoms, and/or in preventing such illnesses and/or symptoms.
  • a powdered drug and a liquid used for a diluent other combinations of mixed materials may also be used according to embodiments described herein. For example, two liquids may be combined, two powders may be combined, a powder and a combination liquid, etc.
  • Exemplary embodiments described herein include reconstitution auto-injectors and/or systems and/or methods of using a reconstitution auto-injector, such as to administer a drug to a patient.
  • the drug may have been in a powder form and then reconstituted into a mixture for injection.
  • a drug in powder form may comprise a lyophilized drug. It shall be understood a drug need not necessarily be in powder form, and a powder or drug in powder form need not necessarily be a lyophilized drug, as those terms are used herein, and persons of ordinary skill in the art will readily see variations to certain embodiments described herein still encompassed by the present invention as the embodiments discussed herein are exemplary and not limiting.
  • Exemplary embodiments of the reconstitution auto-injector may include a first chamber configured to store a powder therein; and a second chamber configured to store a liquid. Although described herein in terms of the first chamber configured to store and/or in storing a powder, the first chamber may store a liquid. Although described herein in terms of the second chamber configured to store and/or in storing a liquid, the second chamber may store a powder.
  • the reconstitution auto-injector may comprise a third chamber configured to store a second liquid.
  • the reference to a first, second, and/or third is intended to identify one chamber or liquid etc. from another and is not intended to specify a specific number of elements or in defining an order. Therefore, for example, the first chamber may be the second chamber or vice versa when describing different exemplary embodiments of the invention.
  • the first chamber and the second chamber may be positioned side by side and separated by a separator.
  • the reconstitution auto-injector may include a body.
  • the body may comprise an outer body at a first end and an inner body at a second end.
  • the second end may include an end of the reconstitution auto-injector configured to be positioned adjacent an injection site during use.
  • a portion of the inner body may be positioned within a portion of the outer body.
  • the outer body may move independently of the inner body.
  • the inner body may slide longitudinally within the outer body. The configuration and/or positions of the inner body and outer body may provide for the automatic actuation of the reconstitution auto-injector to recombine a drug and administer it to a patient through injection.
  • the first chamber may be configured to retain and/or may retain a powder positioned therein
  • the second chamber may be configured to retain and/or may retain a liquid positioned therein.
  • the separator between the first chamber and the second chamber may include a flow channel providing fluid communication between the first chamber and the second chamber.
  • the reconstitution auto-injector may also include a stopper positioned within the second chamber to obstruct the flow channel so that the first chamber and the second chamber are not in fluid communication in a first configuration or position of the stopper.
  • the configuration of the chambers and/or stopper may permit the separation of a drug and its diluent for long term storage.
  • the configuration of the chambers and/or stopper and/or flow channel may be configured to permit the reconstitution of a drug and diluent upon activation of the reconstitution auto-injector, e.g. to more easily administer a combination drug to a patient.
  • Exemplary embodiments may also use a liquid, which may comprise the diluent, and/or a gas to assist in the reconstitution of the drug by mixing the powder and the liquid.
  • a liquid which may comprise the diluent, and/or a gas to assist in the reconstitution of the drug by mixing the powder and the liquid.
  • the reconstitution auto-injector may include a first power source and a second power source.
  • the first power source may be in communication with a first plunger and configured to move the first plunger away from the first power source
  • the second power source may be in communication with a second plunger and configured to move the second plunger away from the second power source.
  • a power source is understood not to just include electrical power but mechanical power, such as movement and/or actuation of the system components for automatic reconstitution and/or automatic injection of the reconstituted drug.
  • the second power source may be activated by pressure on the inner body as the reconstitution auto-injector is pressed against an injection site (e.g. of a patient).
  • the second power source may include a compressed second spring configured to release upon activation and extend to move a second plunger rod and the second plunger away from the second power source and compress a volume of the second chamber comprising the liquid.
  • the first power source may include a compressed first spring configured to release upon activation and extend to move a first plunger rod and the first plunger away from the first power source and compress a volume of the first chamber.
  • the reconstitution auto-injector may include an actuator positioned between the first plunger and the first power source to release the first spring as the first plunger is moved toward the first power source.
  • the reconstitution auto-injector may also include a needle, a needle stopper, and (optionally) an end cap.
  • the needle stopper may be positioned within the first chamber adjacent the end cap.
  • the needle may extend into the needle stopper and may move through the needle stopper and end cap when the first plunger pushes against a terminal end of the needle.
  • the needle may have a pointed end on an opposite end of the needle from the terminal end pushed on by the first plunger.
  • the reconstitution auto-injector may optionally include a safety cap.
  • Exemplary embodiments described herein may include a method of using a reconstitution auto-injector.
  • the method may include providing the reconstitution autoinjector; activating the reconstitution auto-injector; reconstituting a drug in powder form into a reconstituted mixture; and injecting the reconstituted mixture into an injection site (e.g., a patient).
  • the method may further comprise injecting a second liquid from a third chamber into the injection site.
  • the reconstitution auto-injector used in the method may have any combination of the components described herein.
  • the reconstitution auto-injector may have a powder (e.g., the drug in powder form) contained in a first chamber and a liquid contained in a second chamber. The powder and liquid may be separated from each other in a first configuration prior to use.
  • Exemplary embodiments of the method described herein may include activating the reconstitution auto-injector by pressing the reconstitution auto-injector against the injection site (e.g., a patient’s skin) to automatically trigger the reconstitution and the injection.
  • the method may include, during the activation, releasing a compressed second spring to move a second plunger in a direction away from the second spring and toward the injection site.
  • the method may include opening a flow channel between the second chamber and the first chamber so that as the second plunger moves away from the second spring, the liquid moves into the first chamber.
  • the method may include applying a gas through the flow channel after the liquid from the second chamber moves into the first chamber to agitate the liquid with the drug in powder form creating a reconstituted mixture, and blocking the flow channel with the second plunger.
  • the method may include actuating a compressed first spring by moving a first plunger in the first chamber as the first chamber is filled with the liquid from the second chamber, thereby releasing the first spring and applying a force on the first plunger to move the first plunger away from the first spring and toward the injection site.
  • the method may include moving a needle within the first chamber with the first plunger through a needle stopper and out an end cap.
  • the method may include dispelling gas contained within the first chamber through the needle after an end of the needle exits the needle stopper, while the end of the needle is within a gap created by the end cap and before the end of the needle enters the injection site (e.g., a patient’s skin).
  • the method may include moving the needle into the injection site while dispensing the reconstituted mixture (e.g., into a patient).
  • a reconstitution auto-injector having a body including a first chamber configured to store a powder therein; a first plunger within the first chamber; a first power source configured to push the first plunger and reduce a volume within the first chamber; an actuator configured to trigger the first power source; a second chamber configured to store a liquid; a second plunger in the second chamber; a second power source configured to push the second plunger and reduce a volume within the second chamber; and a flow channel between the first chamber and the second chamber such that the liquid can flow into the first chamber when the second plunger is moved by the second power source.
  • the reconstitution auto-injector could also comprise a third chamber configured to store a second liquid therein, and could also include a bladder between the first chamber and the third chamber to separate the powder from the second liquid in a storage position.
  • the first plunger, actuator, and first power source may be configured such that the actuator automatically triggers the first power source when the liquid of the second chamber flows into the first chamber and moves the first plunger in a first direction to increase the volume of the first chamber.
  • the first power source may be configured to, upon being triggered, push the first plunger in an opposite direction to reduce the volume within the first chamber.
  • the reconstitution auto-injector may include a stopper configured to cover the flow channel in a first configuration, and uncover the flow channel in a second configuration.
  • the second configuration may be configured to occur when the liquid in the second chamber is compressed by the second plunger after activation of the second power source.
  • Exemplary embodiments of the methods of using a reconstitution auto-injector described herein may include providing the reconstitution auto-injector having a first chamber having a drug in powder form contained therein, a second chamber having a liquid contained therein, a first power source, and a second power source; activating the second power source to compress the liquid to flow from the second chamber to the first chamber; reconstituting the drug in powder form into a reconstituted mixture; and automatically activating the first power source to inject the reconstituted mixture into an injection site (e.g., a patient).
  • the reconstitution auto-injector may further comprise a third chamber having a second liquid contained therein, wherein automatically activating the first power source to inject the reconstituted mixture also injects the second liquid into the injection site.
  • the method may include the automatic activation of the first power source through movement of a first plunger in a first direction, the first power source configured to, upon activation, move the first plunger in a second direction opposite the first direction.
  • the method may include the activation of the second power source by pressing the reconstitution auto-injector against the injection site (e.g., a patient’s skin).
  • the method may include keeping the first chamber and second chamber out of fluid contact through a stopper over a flow channel, and then permitting fluid flow from the second chamber to the first chamber by moving the stopper from the flow channel.
  • FIG. 1 illustrates a perspective view of an exemplary auto-injector according to embodiments of the invention.
  • FIG. 2A illustrates a side view of the exemplary auto-injector according to embodiments of the invention.
  • FIG. 2B illustrates a cross sectional view to illustrate internal component parts of the system according to embodiments of the invention.
  • FIGS. 3A-3B illustrate exemplary features of the auto-injector according to embodiments of the invention including a safety feature and the auto-injector during a safety release portion of the method for administering a drug using an auto-injector according to embodiments described herein.
  • FIG. 4 illustrates a cross sectional view of the auto-injector during an activation portion of the method for administering a drug using an auto-injector according to embodiments described herein.
  • FIGS. 5-7 illustrate cross sectional views of the auto-injector during a reconstitution portion of the method for administering a drug using an auto-injector according to embodiments described herein.
  • FIGS. 8-9 illustrate cross sectional views of the auto-injector during an injection portion of the method for administering a drug using an auto-injector according to embodiments described herein.
  • FIG. 10 illustrates a cross sectional view of a portion of the auto-injector after completing the method for administering the drug using the auto-injector.
  • FIG. 11 illustrates an exemplary embodiment having additional/multiple chambers as described herein.
  • Exemplary embodiments of the system described herein may include one or more benefits.
  • exemplary embodiments of the systems and methods described herein may meet the Federal Drug Administration’s (FDA’s) contemporary emergency-use devices’ reliability requirements.
  • the systems and methods described herein may reconstitute a drug into a mixture prior to the injection process.
  • the system such as through the use of one or more automatic power source(s), may be configured to automate the reconstitution and/or injection process so that user interfaces or steps are minimized.
  • Device interfaces may be used that are compatible with current devices, and/or may be configured to permit the addition of a needle shield and/or cover.
  • Exemplary embodiments may have the liquid comprise a second liquid state drug (or combination of additional drugs) to administer a two or more drug combination.
  • exemplary embodiments may include a safety feature such as a safety pin at the front of the device.
  • FIG. 1 illustrates a perspective view of an exemplary reconstitution auto-injector according to embodiments of the invention.
  • Exemplary embodiments of the reconstitution auto-injector described herein include a first chamber configured to store a powder therein, and a second chamber configured to store a liquid.
  • the reconstitution auto-injector also may include a third chamber configured to store a second liquid.
  • the chambers may be contained within a body.
  • the first chamber and the second chamber may be within the inner body 20 and positioned side by side and separated by a separator.
  • FIG. 1 illustrates an exemplary exterior body that may be configured to enclose and/or define the first chamber and the second chamber.
  • the body may include an outer body 19 at a first end and an inner body 20 at a second end of the reconstitution auto-injector.
  • the second end of the reconstitution auto-injector includes an end cap 21 at the end of the inner body 20 configured to be positioned adjacent an injection site during use.
  • a portion of the inner body 20 may be positioned within a portion of the outer body 19.
  • FIG. 2A illustrates a side view of the exemplary reconstitution auto-injector according to embodiments of the invention.
  • FIG. 2B illustrates a cross sectional view of FIG. 2A to illustrate internal component parts of the system according to embodiments of the invention.
  • the exemplary reconstitution auto-injector may include an outer body 19 and an inner body 20.
  • a portion of the inner body 20 may be positioned within a portion of the outer body 19 and extend out an end of the outer body 19.
  • the inner body 20 may be at an end of the reconstitution auto-injector to define an end to be positioned at the injection site.
  • the inner body 20 and outer body 19 may define a first interior space 7 and a second interior space 6.
  • the first interior space 7 may have positioned therein a first plunger 17 and the second interior space 6 may have positioned therein a second plunger 11.
  • the area within the first interior space 7 from the first plunger 17 to an end of the first interior space 7 toward the injection site (and away from the first power source 1) may define a first chamber.
  • the area within the second interior space 6 from the second plunger 11 to an end of the second interior space 6 toward the injection site (and away from the second power source 2) may define a second chamber.
  • the first chamber may be configured to retain and may have retained therein a powder 24.
  • the second chamber may be configured to retain and may have retained therein a liquid 23.
  • the second chamber may be subdivided into one or more sections, such as a first section configured to retain the liquid 23 therein and a second section configured to retain a gas 22 therein.
  • the first section and second section may be in fluid communication and divided simply by the separation of the gas 22 from the liquid 23 and the positioning of the system such that the liquid 23 is positioned toward the end closest to the injection site, and the gas 22 is positioned away from the end.
  • the first section and the second section may also include a barrier or other separation between the first section and the second section.
  • the barrier may be configured to move within the inner body 20 such that the second plunger 11 may be configured to compress a gas 22 within the second section to push on the barrier and then compress the liquid (such as a diluent) 23 within the second section.
  • the first plunger 17 and the second plunger 11 are positioned within the inner body 20 to define the first chamber and the second chamber.
  • the first chamber and the second chamber may be positioned side by side toward an end of the system configured to be positioned adjacent the injection site (and opposite from an end of the system comprising the first and/or second power source(s) 1, 2).
  • the inner body 20 may comprise a separator between the first chamber and the second chamber.
  • the separator may comprise a flow channel 8 permitting fluid flow between the first chamber and the second chamber through the flow channel 8.
  • the second chamber may have positioned therein a stopper 12 coupled to a plug 13.
  • the stopper may be positioned to obstruct the flow channel 8 in a first configuration or position and permit fluid flow through the flow channel 8 in a second configuration or position.
  • the second position is when the stopper 12 is moved toward the end of the system configured to be positioned adjacent the injection site, compressing or moving along the plug 13.
  • the first chamber and second chamber may therefore be separated and not in fluid communication when the stopper 12 is in the first position and may be in fluid communication through the flow channel 8 when the stopper 12 is in the second position.
  • the inner body 20 may include an end cap 21.
  • the end cap 21 may be on a same side of the body as the first chamber and may be positioned at the end of the first chamber toward the end of the system to be positioned adjacent to the injection site during use.
  • the inner body 20 may comprise an opening such that the end of the first chamber is open through the inner body 20.
  • the inner body 20 may have a needle stopper 15 and end cap 21 to close the opening of the inner body 20 and enclose the first chamber.
  • a needle 16 may have a sharp end for penetrating an injection site.
  • the sharp end may be positioned toward the end of the reconstitution auto-injector system configured to be positioned adjacent the injection site during use.
  • the sharp end of the needle 16 may be positioned within a portion of the needle stopper 15.
  • the opposite end of the needle 16 is configured to abut the first plunger 17 and not penetrate the first plunger 17.
  • the first plunger 17 may therefore be configured to move within the first chamber, apply force to the needle 16 (from the first power source 1 as described herein), and move the needle 16 through the needle stopper 15 and end cap 21.
  • the first plunger 17 may be positioned within the inner body 20 and the first interior space 7 to move within the first chamber toward and away from the needle 16 according to the method described herein.
  • the first plunger 17 may have an exterior profile that is approximately equal to or minutely smaller than an interior profile of the first interior space 7 and/or first chamber so that the first plunger 17 may slide within the first interior space 7 and the first chamber.
  • the end cap 21 may be configured to separate the end of the needle 16 after it leaves the needle stopper 15 and before the needle 16 is injected into an injection site (e.g., of a patient).
  • the end cap 21 may include a gap to create the separation. The separation may permit the first plunger 17 to move within the first chamber for a sufficient distance to dispel captured gas therein (e.g., gases 22, 25) through the needle 16 before the needle 16 penetrates the injection site (e.g., the patient) and the reconstituted mixture is administered (e.g., to a patient).
  • captured gas therein e.g., gases 22, 25
  • the first chamber includes gas 25 and powder 24.
  • the second chamber includes gas 22 and liquid 23.
  • the gases 22, 25 may be any gas, such as air, and may be different from or the same as each other.
  • the exemplary gases may be inert to the administered drug or other component parts such as the powder 24 or liquid 23.
  • the powder 24 comprises a drug (e.g., in powder form).
  • the drug may be freeze dried or in other powdered or other form.
  • the drug may comprise a lyophilized solid state drug.
  • the liquid 23 may be a diluent used to reconstitute the drug.
  • the liquid 23 may comprise a second drug or other combination of drugs, vitamins, minerals, activators, or other composition to assist in the administration of the drug (e.g., to a patient).
  • the powder 24 may be any powdered material intended to be reconstituted and injected into a site. The injection of a drug is sometimes described herein with respect to a patient. However, any injection site for injection of a reconstituted substance may be considered within the scope of the present disclosure. For example, humans, mammals, animals, and/or other creatures, including of different ages, may also benefit from exemplary embodiments described herein.
  • the exemplary auto-injector may comprise a first power source 1, and a second power source 2.
  • the first power source 1 may include a first inner tube 4 having positioned therein a first spring 26 in communication with a first plunger rod 10 connected to a first plunger 17 in order to move the first plunger 17 through a first chamber volume and toward an end of the reconstitution auto-injector system configured to be positioned at an injection site.
  • the second power source 2 may include a second inner tube 5 having positioned therein a second spring 27 in communication with a second plunger rod 9 connected to a second plunger 11 in order to move the second plunger 11 through a second chamber volume and toward the end of the system configured to be positioned at the injection site.
  • the first power source 1 and the second power source 2 may each be configured in a first position in which the first spring 26 and second spring 27 are compressed and the first plunger rod 10 and the second plunger rod 9 are in retracted positions (positioned away from the injection site). Once activated, the spring 26, 27 is released so that the spring 26, 27 extends and applies a force through the plunger rod 10, 9 and moves the plunger 17, 11 toward the end of the system positioned at the injection site, thereby compressing the space 7, 6 and the chambers.
  • the first power source 1 and the second power source 2 are configured to operate sequentially and automatically, such that after the second power source 2 is actuated, the second spring 27 is released to elongate the second spring 27, move the second plunger 11, and actuate the first power source 1, releasing the first spring 26 to elongate the first spring 26 and move the first plunger 17 toward the needle 16.
  • the auto-injector may also include an actuator 18.
  • the actuator 18 may be positioned between the first plunger 17 and toward first power source 1.
  • the actuator 18 may move within the first interior space 7 and be pushed toward the first power source 1 as the first chamber is filled by the liquid 23 during the processes described herein.
  • the actuator 18 may release the first spring 26 to activate the first power source 1.
  • the first spring 26 When the first power source 1 is activated, the first spring 26 may be released and the first spring 26 elongates thereby applying a force through the first plunger rod 10 to move the first plunger rod 10 toward the first plunger 17 and toward the needle 16, to move the needle 16 through the needle stopper 15, out the end cap 21, and into the injection site (e.g., a patient).
  • the auto-injector may automatically actuate the second power source 2 during use.
  • the inner body 20 may be configured at its end, such as through the end cap 21, to contact and he positioned adjacent to an injection site (e.g., at a patient’s skin).
  • the outer body 19 may be held by a practitioner injecting a drug mixture into a patient.
  • the second power source 2 is actuated, thereby releasing the second spring 27.
  • first plunger 17 moves in the direction of first power source 1 as liquid 23 is being transferred from the second chamber to the first chamber.
  • the liquid 23 applies pressure on first plunger 17 displacing it to press on to the actuator 18.
  • the actuator 18 can then press on to the first power source 1’s inner tube 4 releasing the first power source 1’s spring 26.
  • the system may comprise a safety cap 3 (also referred to herein as a safety pin).
  • the safety cap 3 may be positioned on a second end of the system away from the end that is configured to be positioned at the injection site.
  • the safety cap 3 may cover the first and/or second power sources 1, 2 to minimize the inadvertent activation of the system until the autoinjector is ready for use.
  • the safety cap 3 may be positioned about the second end of the system and cover an exposed portion of the first power source 1 and an exposed portion of the second power source 2.
  • the safety cap 3 may be optional.
  • the system may also include a disc 14.
  • the disc 14 may be positioned adjacent the needle stopper 15.
  • the disc 14 may be positioned between the needle stopper 15 and the flow channel 8 and define a terminal end of the first chamber in which the 1 drug (whether in powder form or recombined in a liquid) is configured to contact.
  • the disc 14 may therefore provide a barrier between the drug and the needle stopper 15.
  • each of the power sources 1, 2 comprise a spring 26, 27 positioned within a tunnel.
  • the spring 26, 27 is illustrated as a coil spring positioned about a shaft, wherein the shaft couples to the plunger rod 10, 9.
  • Each shaft comprises a flange positioned along the length of the shaft and extending radially outward from the shaft and circumferentially about the shaft.
  • Each flange is configured to contact a terminal end of the spring 26, 27.
  • the spring 26, 27 may therefore elongate and apply a force to the flange and thereby move the plunger rod 10, 9.
  • the plunger rod 10, 9 may thereafter contact the plunger 17, 11 to move the plunger 17, 11 to compress the volume of the chambers.
  • Exemplary embodiments may include other configurations of the plunger 17, 11, plunger rod 10, 9, actuator 18, and force mechanism (such as a spring 26, 27) that may be configured to operate in the same way.
  • force mechanism such as a spring 26, 27
  • different spring configurations may be used, and/or the spring mechanism may be integrated into the shaft, such as by a selection of a compressible/expandable material.
  • a drug is reconstituted and administered automatically.
  • the method may comprise any combination of steps as described herein.
  • the auto-injector is provided including a first chamber having a powder and a second chamber having a liquid.
  • the method may include activating a second power source to apply pressure to the liquid and opening a fluid flow channel between the first chamber and the second chamber so that the liquid is transferred under pressure from the second chamber into the first chamber.
  • the method may include applying gas to the first chamber through the flow channel to agitate the powder and the liquid to create a reconstituted mixture.
  • the method may include activating a second power source to apply pressure to a first plunger of the first chamber.
  • the second power source may be configured to move the needle, such as if the second power source continues to apply force to the needle to move the needle.
  • the method may include continuing to move the needle by the second power source through a needle stopper to exhaust the gas from the first chamber.
  • the method may include moving the needle toward and into the injection site.
  • the needle may access the reconstituted mixture and permit the reconstituted mixture to be administered through the needle and into the injection site.
  • the method further comprises injecting a second liquid from a third chamber.
  • a reconstitution auto-injector may be provided according to embodiments described herein.
  • the auto-injector may comprise a two-chamber system in which a first chamber is configured to store a powder, such as a lyophilized solid-state drug, and a second chamber configured to store a liquid (e.g., diluent).
  • the auto-injector may comprise a three- chamber system in which a third chamber is configured to store a second liquid.
  • the autoinjector may also comprise a second power source configured to mix the powder with the fluid (e.g., diluent), and a first power source configured to administer the reconstituted drug (and in some embodiments also the second liquid).
  • the second chamber After the diluent is transferred into the first chamber, the second chamber’s gas is transferred through the flow channel thereby bubbling gas into the reconstituted drug and agitating it to increase reconstitution and create a reconstituted mixture.
  • the second power source continues to apply pressure and compress the gas in the second chamber, while moving to its final position and closing the flow channel.
  • the compressed gas may apply a load on the first plunger and displace the first plunger in the direction of the first power source.
  • the first plunger may, after a duration, push an actuator, which can push on an inner tube of the first power source and release a first spring of the first power source.
  • the first spring may release and push against the first plunger in a direction of the injection site compressing the contents (e.g., gas, reconstituted mixture) in the first chamber.
  • the first spring may continue to apply force on the first plunger, which may cause the first plunger to push against the needle.
  • the first spring continues to apply force on the first plunger, the needle accesses the reconstituted mixture, and the reconstituted mixture flows through the needle orifice and into the injection site.
  • the first spring continues to apply force on the first plunger, and the needle continues to deploy in the injection site, while simultaneously injecting the reconstituted mixture (e.g., a drug or combination drug).
  • the reconstituted mixture e.g., a drug or combination drug
  • the first spring continues to apply force on the first plunger, and the needle deployment is completed, and drug delivery continues until the required volume of drug is administered.
  • FIGS. 3A-10 illustrate exemplary features of the reconstitution auto-injector during the method for administering a drug using an auto-injector according to embodiments described herein.
  • the method may comprise a safety release portion, an activation portion, a reconstitution portion, an injection portion, and may thereafter be complete.
  • the safety release portion may be optional.
  • FIGS. 3A-3B illustrate exemplary features of the auto-injector according to embodiments of the invention including a safety feature and the auto-injector during a safety release portion of an exemplary method for administering a drug using an auto-injector according to embodiments described herein.
  • the illustrations of FIGS. 3A-3B show the safety cap 3, which may be a safety pin removed from a terminal end of the system, thus separating the cap from the outer body 19.
  • the reconstitution auto-injector system may be received in packaging.
  • the system may therefore be removed from the packaging.
  • the reconstitution auto-injector may be held (e.g., with one hand) on the outer body 19.
  • a holder e.g., the other hand
  • FIG. 4 illustrates a cross sectional view of the auto-injector during an activation portion of an exemplary method for administering a drug using an auto-injector according to embodiments described herein.
  • the end cap 21 when the reconstitution auto-injector is ready for use, the end cap 21 (which may be referred to as a nose of the device) may be positioned to contact the injection site (e.g., a patient).
  • the end cap 21 of the system may be positioned adjacent the injection site, and the system ready to use.
  • the method may include pressing the reconstitution auto-injector system against the injection site.
  • the injector body 33 an interior portion of the outer body 19
  • the injector body 33 and the inner body 20 may both move independent of the outer body 19.
  • the power sources 1, 2 are attached to the outer body 19, so the injector body 33 can move towards the terminal end of the reconstitution auto-injector system (e.g., toward the end with the power sources 1, 2).
  • the injector body 33 may press on the second inner tube 5 of the second power source 2.
  • the second power source 2 may be activated first and may be used through respective second and first plungers to automatically activate the first power source 1 that is activated second.
  • the first activated power source is described herein as the second power source 2 and the second activated power source is described herein as the first power source 1. Therefore, second power source 2 gets activated first to reconstitute the powder (e.g., drug), and first power source 1 gets activated after the mixture is reconstituted, so that it can inject the mixture (e.g., into the patient).
  • the second spring 27 is released, and the second spring 27 applies a force on the second plunger rod 9.
  • FIGS. 5-7 illustrate cross sectional views of the auto-injector during a reconstitution portion of an exemplary method for administering a drug using an auto-injector according to embodiments described herein.
  • the method may include moving the second plunger rod 9 (diluent chamber plunger rod) in the direction of the injection site, compressing the gas 22 within the second chamber and displacing the liquid 23 (diluent).
  • the stopper 12 gets displaced by the compressed gas 22 and liquid 23, and the plug 13 disengages from the injector body.
  • the stopper 12 then moves to its final position toward the end of the reconstitution auto-injector adjacent the injection site.
  • the second plunger 11 applies force
  • the second plunger 11 causes the liquid 23 (diluent) to flow into the first chamber (powder chamber) through the flow channel 8.
  • the second plunger displaces the liquid
  • the space within the first chamber fills and through the addition of the liquid 23 within the first chamber (and/or compression of gas within the first chamber), a load is applied to the first plunger 17 (powder chamber plunger).
  • the liquid 23 is injected into the first chamber, the liquid 23 (and/or gas) within the first chamber move the first plunger 17 away from the end cap 21 (or needle 16).
  • the diluent starts to reconstitute the powder 24.
  • the second plunger 11 displaces gas within the second chamber (diluent chamber gas/air) into the first chamber (powder chamber), thereby mixing the powder 24 and liquid 23.
  • the addition of the gas from the second chamber into the first chamber through the flow channel 8 creates a bubbling to agitate a drug and liquid to increase the drug reconstitution.
  • the second plunger 11 compresses gas into the liquid/powder 23/24 in the first chamber and is finally positioned adjacent the flow channel 8, thereby closing the flow channel 8 and retaining the fluid/powder 23/24 within the first chamber.
  • additional pressure may be created in the first chamber (powder chamber) during the compression of additional gas from the second chamber into the first chamber before the second plunger 11 reaches the end of the second chamber.
  • the compressed gas applies a force on the first plunger 17 (powder chamber plunger) thereby moving the first plunger in the direction of the first power source 1 and away from the end of the system adjacent the injection site (end cap 21).
  • the first plunger 17 moves toward the first power source 1
  • the first plunger 17 applies a force and moves an actuator 18, which thereafter presses onto the first inner tube 4 and activates the first power source 1.
  • the first spring 26 is released, and elongates.
  • the first spring 26 applies a force on the first plunger rod 10 (powder chamber plunger rod) and therethrough displaces the first plunger 17 (powder chamber plunger) in the direction away from the first power source 1 and toward the needle 16 or end cap 21 of the system adjacent the injection site.
  • the first plunger 17 is moved toward the reconstituted mixture 23/24 and compresses the first chamber contents.
  • FIGS. 8-9B illustrate cross sectional views of the reconstitution auto-injector during an injection portion of an exemplary method for administering a drug using an auto-injector according to embodiments described herein.
  • the first plunger 17 (powder chamber plunger) is displaced in the direction of the reconstituted mixture 23/24 and compresses the contents (which may include, e.g., gas) within the first chamber and pushes the needle 16 through the needle stopper 15 (powder chamber stopper). Compressed gas may be exhausted, after the needle stopper 15 is punctured, into the space between the injection site and the needle stopper 15 created by the end cap 21.
  • contents which may include, e.g., gas
  • the first power source and the first plunger 17 continue to push the needle 16 into the injection site.
  • the needle 16 moves through the reconstituted mixture 23/24.
  • the needle 16 comprises a sharp end for penetrating the injection site (e.g., a patient’s skin).
  • the opposite end of the needle 16 comprises an orifice (e.g., on a side of the needle 16) to provide access to the reconstituted mixture (e.g., a drug or combination drug) for delivery through a hollow passage in the needle 16 from the orifice to an opening at the sharp end of the needle 16.
  • FIG. 10 illustrates a cross sectional view of a portion of the reconstitution auto-injector after completing an exemplary method for administering a drug using an auto-injector according to embodiments described herein.
  • a reserve drug volume/dose 29 may be available in case the device is activated upside-down or in a compromised drug administration position, and/or if some amount of drug is squirted out of the system prior to the needle penetrating the injection site.
  • the system may be designed so that the reserve volume 29 is not injected out of the device if the device is activated in the natural position.
  • the reserve volume may be stored in a residual volume space, such as within a space by a residual volume disc 28 and/or within a volume by needle stopper 15 in the first chamber.
  • FIG. 11 illustrates an exemplary embodiment having additional chambers (e.g., for administering additional medications to a recipient). As illustrated, a third chamber 1132 is provided for a second liquid, but any number of additional chambers may be used to administer additional materials.
  • the triple-chambered reconstitution auto-injector system 1100 displayed in FIG. 11 may include a needle 1116 and two power sources 1101, 1102.
  • This system may include two chambers having a liquid/non-liquid combination to be able to reconstitute a drug, such as first and second chambers 1106, 1107.
  • These chambers and system components and configurations may be similar to those described herein.
  • the system 1100 may include, for example, the power sources 1101, 1102 for sequentially activating so that a liquid is injected from second chamber 1106 to first chamber 1107 containing a powdered material to be reconstituted.
  • the system 1100 may include one or more additional liquid chambers (e.g., third chamber 1132) for administering additional material (e.g., to a patient).
  • additional liquid chambers e.g., third chamber 1132
  • Exemplary embodiments of the system 1100 may be configured to automatically first reconstitute and then administer a powder/lyophilized drug; and thereafter, administer a second liquid drug.
  • the system 1100 may use a two-step safety release and activate emergency-use auto-injectors’ drug administration procedure, as described herein.
  • the second power source 1102 may be activated to mix the powder/lyophilized drug from a first chamber 1107 with its diluent from a second chamber 1106, thereby reconstituting the drug.
  • the reconstitution may be according to exemplary system configurations and methods described herein (such as those associated with FIGS. 1-10).
  • the first power source 1101 is automatically activated to insert the needle 1116 across different injection depths (e.g., intramuscularly) and administer the reconstituted drug, as well as a second liquid from third chamber 1132, across the different injection depths.
  • injection depths e.g., intramuscularly
  • an exemplary auto-injector includes a reconstitution autoinjector system 1100, comprising a body having: a first chamber 1107 configured to store a powder therein; a second chamber 1106 configured to store a liquid; and a third chamber 1132 configured to store a second liquid.
  • a reconstitution auto-injector system 1100 comprising a body having: a first chamber 1107 configured to store a powder therein; a second chamber 1106 configured to store a liquid; and a third chamber 1132 configured to store a second liquid.
  • Exemplary embodiments described herein include a method of using a reconstitution auto-injector such as 1100, comprising: providing the reconstitution auto-injector; activating the reconstitution auto-injector; reconstituting a drug in powder form into a reconstituted mixture; injecting the reconstituted mixture into an injection site (e.g., a patient); and injecting the second liquid from the third chamber 1132.
  • the system 1100 may include a body with a first side and a second side.
  • the first and second sides may be separated with a separator therebetween with a flow channel and a stopper positioned thereon to separate the first and second side.
  • Each side may include one or more different chambers.
  • Each chamber of the one or more chambers on each side may be longitudinally positioned along the body on a side of the system 1100.
  • a first chamber 1107 may be longitudinally positioned and separated from a second chamber 1106 (and any more sequential chambers if present positioned along one or both sides of the system).
  • Each chamber on the same side of the system may be separated with a bladder.
  • the system may include a first chamber 1107 at a distal end of the system containing a powder as described herein to be reconstituted by a liquid positioned in a second chamber 1106 on the opposite side of the system.
  • a second liquid may be contained in a third chamber 1132 positioned toward a proximal end of the system 1100 from the first chamber 1107.
  • system 1100 comprises an outer body at its distal end and inner body at its proximal end, wherein the inner body comprises the first and second power sources 1101, 1102 and the outer body comprises the first, second, and third chambers 1107, 1106, 1132.
  • An outer body need not necessarily be at the distal end, and an inner body need not necessarily be at the proximal end (e.g., see the embodiments of FIGS. 1-10).
  • an inner body need not necessarily comprise the power sources, and an outer body need not necessarily comprise the chambers (e.g., see the embodiments of FIGS. 1-10).
  • power sources and chambers may be at any body, end, and/or side, and variations will be readily apparent to those of ordinary skill in the art.
  • the terms first, second, third, etc. are used to differentiate components but not to dictate, limit, mandate, or necessitate any arrangement, configuration, order, or sequence.
  • a first power source 1101 may be on a second side or vice versa
  • a second chamber 1106 may be on a first side or vice versa, etc.
  • variations will be readily apparent to those of ordinary skill in the art.
  • the first power source 1101 is used to inject the reconstituted mixture and the second liquid (e.g., into a patient).
  • the first power source 1101 may be activated to push a first plunger against the second liquid in the third chamber at the proximal end of the system 1100.
  • the second liquid is compressed and the bladder between the first chamber 1107 and the third chamber 1132 is moved to push the needle 1116 (e.g., into the patient).
  • the reconstituted mixture is then injected after the needle 1116 is inserted into the injection site, and the reconstituted mixture is pushed from the first chamber 1107 through an orifice at the proximal end of the needle 1116 and into the injection site.
  • the second liquid in the third chamber 1132 is moved to the distal end of the system 1100.
  • the second liquid contained in the third chamber 1132 then passes into the needle 1116, e.g. through a bypass passage in the body.
  • the second liquid in the third chamber 1132 may bypass the bladder and be in fluid communication with the needle 1116 to inject the second liquid into the injection site.
  • Other bypass options may also be used, such as valve(s) in the bladder, bypass passage(s), or other method(s).
  • An exemplary embodiment of the system described herein may include a system 1100 having a first side and a second side, where the first side and second side may be separated except for a flow channel therebetween to permit fluid flow therethrough.
  • the system may include a stopper to obstruct the flow channel and obstruct the fluid path between the first side and second side, separating each from the other in a first configuration.
  • the stopper may be movable during the operation of the system 1100 as described herein so that the first side and second side are in fluid communication in a second configuration.
  • the first side and/or the second side may each include one or more chambers.
  • the second side may include a second chamber 1106 configured to contain a liquid.
  • the first side may include a first chamber 1107 and a third chamber 1132.
  • the first chamber 1107 and third chamber 1132 may be separated with a bladder.
  • the first chamber 1107 and third chamber 1132 may be longitudinally displaced along the system 1100.
  • a first chamber 1107 may therefore be positioned at the distal end of the system 1100 configured to or having contained therein a powder to be reconstituted with the liquid from the second chamber 1106.
  • the third chamber 1132 may be proximally positioned relative to the first chamber 1107.
  • the third chamber 1132 may be configured to hold a second liquid.
  • the first chamber 1107 and third chamber 1132 may be separated by a bladder wherein the bladder may have coupled thereto a needle 1116 for injection (e.g., into a patient).
  • the first chamber 1107 and third chamber 1132 may be separated and not in fluid communication in a storage position.
  • the bladder may be moved distally.
  • a reconstituted mixture in the first chamber 1107 may be injected (e.g., into the patient), and the third chamber 1132 may be in fluid communication with the needle 1116 for injecting the second liquid.
  • the system 1100 may be configured such that when actuated a first plunger will push against the proximal chamber of the one or more chambers on a first side (e.g., the third chamber 1132) thereby compressing the contents (e.g., the second liquid) and pushing on the needle 1116/bladder to move the needle 1116 into position (e.g., within the patient).
  • An orifice at the proximal end of the needle 1116 may permit a reconstituted mixture (and second liquid, possibly with additional materials) to be injected (e.g., into the patient).
  • the sequential activation of the two power sources 1102, 1101 may be used to enable the two steps of reconstituting the powder (e.g., lyophilized drug), and thereafter administer the two or more materials, i.e. the reconstituted mixture and second liquid with or without additional substances, each of which may comprise one or more drugs, e.g. intramuscularly or otherwise.
  • the powder e.g., lyophilized drug
  • additional substances i.e. the reconstituted mixture and second liquid with or without additional substances, each of which may comprise one or more drugs, e.g. intramuscularly or otherwise.
  • Exemplary embodiments described herein include methods for automatically administering a drug to a patient.
  • the devices may be configured to operate in a two-step safety release and activation process.
  • the method may include a patient (or other user and/or recipient), the removal of a safety release from the autoinjector, and the pushing of the needle end against a location against the patient’s body, such as, for example, a thigh or other body location.
  • the method may include pushing the needle end against the body part and holding the auto-injector in place as the auto-injector administers the drug through the extension of the needle after the drug is reconstituted according to exemplary embodiments described herein.
  • Exemplary embodiments described herein include two separate power sources operating in an automatic and conjoined manner for automatic sequential activation, enabling reconstitution without the need for a user’s intervention (for example, fracturing membranes, vigorous shaking, etc.). Configurations of the two-chamber reconstitution configuration are configured for complete drug reconstitution prior to the start of the injection process.
  • the power sources for exemplary embodiments described herein may be shown and described as spring loaded. However, other power sources are also contemplated herein.
  • the power sources may be any combination of compressed gas or springs or other actuation mechanism.
  • Exemplary embodiments described herein may include automated needle stick protection systems.
  • Embodiments of the present invention may comprise certain drugs, powders, diluents, and/or second liquids, or combinations thereof, with examples provided herein. It shall be known that these examples are non-limiting, and extend to agents in identical or similar classes and/or with identical or similar mechanisms of action, and shall include equivalents with generic or other naming, all of which will be readily apparent to persons having ordinary skill in the art.
  • the scope of the present invention encompasses and is directed to agents spanning various categories, including, for example, antibiotics, anticonvulsants, antidotes, antifungals, antihistamines, anti-inflammatories, antimicrobials, antivirals, immunizations, vaccinations, and sympathetic and parasympathetic agonists and antagonists.
  • a drug and/or powder may comprise at least one item selected from the group consisting of: acyclovir, albuterol, amoxicillin, amphotericin B, ampicillin, anidulafungin, artesunate, atropine, azithromycin, benzylpenicillin, brincidofovir, buprenorphine, caspofungin, cefazolin, cefepime, cefoperazone, cefotaxime, ceftazidime, ceftriaxone, cefuroxime, cephalexin, cilastatin, clavulanate, clindamycin, clobazam, clonazepam, cloxacillin, cortisone, dantrolene, dexamethasone, diazepam, epinephrine, ertapenem, erythromycin, flumazenil, ganciclovir, hydrocortisone, imipenem, keto
  • a diluent may comprise at least one item selected from the group consisting of: dextrose, lactated Ringer’s, Ringer’s solution, saline, and water. Concentrations may vary and will be readily apparent to persons having ordinary skill in the art.
  • a dextrose solution may comprise 5% dextrose in water (D5), 10% dextrose in water (D10), etc.
  • a saline solution may be hypotonic, such as 0.45% sodium chloride or half normal saline (1/2NS); roughly isotonic, such as 0.9% sodium chloride or normal saline (NS); or hypertonic, such as 3% sodium chloride; etc.
  • a diluent may comprise a combination, such as D5 with NS, D5 with 1/2NS, etc. Other concentrations and/or combinations will be apparent to persons having skill in the art. It shall be understood diluents may further comprise preservatives and/or additives, which will be apparent to persons having skill in the art.
  • a diluent may comprise one or more emollients and/or oils.
  • a powder may comprise the antiviral brincidofovir, offering particular utility in treating viral infection in remote settings, such as, for example, infection with a member of the Ebolavirus genus.
  • a powder may comprise a vaccination, such as those against influenza (flu), tuberculosis (TB), poxviridae, variola viral infection (e.g., smallpox), and varicella-zoster viral infection (e.g., chicken pox and/or shingles).
  • a powder may comprise a polysaccharide conjugate vaccine.
  • One example may comprise the Haemophilus influenzae type B (HIB) vaccine (which may be reconstituted, e.g., in 0.4% saline).
  • HAI Haemophilus influenzae type B
  • a powder may comprise antidotes for nerve gas or pesticide poisoning.
  • a powder may comprise atropine, its diluent may comprise pralidoxime, and their second liquid may comprise scopolamine.
  • a powder may comprise 2-pyridine aldoxime methyl chloride (2PAM) and its diluent may comprise atropine.
  • a powder may comprise atropine, its diluent may comprise sterile water or saline, and their second liquid may comprise pralidoxime.
  • a powder may comprise epinephrine, such as lyophilized epinephrine.
  • its diluent may comprise saline, such as NS (0.9% sodium chloride).
  • Epinephrine in solution may be sensitive to container material, imposing restrictions on storage, transportation, and shelf-life.
  • the possibility of epinephrine in powder form, with the advent of the inventive features of the present invention, allows for a more forgiving and durable product, with improved shelf life and drug stability, including across a wider range of container materials (e.g., plastic).
  • the terms "about,” “substantially,” or “approximately” for any numerical values, ranges, shapes, distances, relative relationships, etc. indicate a suitable dimensional tolerance that allows the part or collection of components to function for its intended purpose as described herein.
  • Numerical ranges may also be provided herein. Unless otherwise indicated, each range is intended to include the endpoints, and any quantity within the provided range. Therefore, a range of 2-4, includes 2, 3, 4, and any subdivision between 2 and 4, such as 2.1, 2.01, and 2.001. The range also encompasses any combination of ranges, such that 2-4 includes 2-3 and 3-4.

Landscapes

  • Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

L'invention concerne des systèmes et des procédés de reconstitution automatique d'un médicament, puis de leur administration à un patient. Le système et les procédés peuvent faire appel à un auto-injecteur de reconstitution ayant une première chambre contenant une poudre, une seconde chambre contenant un liquide, une première source d'alimentation et une seconde source d'alimentation. La première source d'alimentation peut être activée pour comprimer le liquide afin qu'il s'écoule dans la première chambre avec la poudre. La seconde source d'alimentation peut s'activer pour injecter le médicament reconstitué chez le patient.
PCT/US2024/031099 2023-05-25 2024-05-24 Système auto-injecteur Pending WO2024243553A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363504439P 2023-05-25 2023-05-25
US63/504,439 2023-05-25

Publications (2)

Publication Number Publication Date
WO2024243553A2 true WO2024243553A2 (fr) 2024-11-28
WO2024243553A3 WO2024243553A3 (fr) 2025-03-13

Family

ID=93589888

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/031099 Pending WO2024243553A2 (fr) 2023-05-25 2024-05-24 Système auto-injecteur

Country Status (1)

Country Link
WO (1) WO2024243553A2 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014503307A (ja) * 2010-12-30 2014-02-13 メリディアン メディカル テクノロジーズ インコーポレイテッド ３つのチャンバを有する自動注射器
JP2017503017A (ja) * 2013-12-18 2017-01-26 ウィンドギャップ メディカル， インコーポレイテッド 薬物混合および送達システムならびに方法
PT3174581T (pt) * 2015-02-19 2018-10-11 Cube Pharmaceuticals N Kalofolias&Co Oe Recipientes de múltipla câmara
US11253506B2 (en) * 2017-08-18 2022-02-22 The Regents Of The University Of Colorado, A Body Corporate Compounds, compositions and methods for preventing and/or treating chlorine inhalation toxicity and/or injury
JP7160949B2 (ja) * 2018-05-29 2022-10-25 エスエイチエル・メディカル・アーゲー 少なくとも１つの物質を分配するための装置及び方法
US12128221B2 (en) * 2020-05-29 2024-10-29 Windgap Medical, Inc. Dynamic mixing and delivery system for mixing a therapeutic agent in an injector or autoinjector

Also Published As

Publication number Publication date
WO2024243553A3 (fr) 2025-03-13

Similar Documents

Publication Publication Date Title
US7503907B1 (en) Medicament cartridge and injection device
JP4755547B2 (ja) 湿／乾自動注射装置
KR100820762B1 (ko) 습식/건식 자동 주사기 조립체
US6149626A (en) Automatic injecting syringe apparatus
EP3498322B1 (fr) Dispositifs d'administration automatique de médicament
US8905975B2 (en) Container, device and method to store and expel a product
CN103796697B (zh) 具有剂量设定装置的柱塞杆和注射装置
KR102492571B1 (ko) 적어도 하나의 물질을 분배하기 위한 장치 및 방법
EP3355968B1 (fr) Unité de seringue à chambres multiples
JPH0460673B2 (fr)
JPH01131671A (ja) 注射器並びに注射器の組立て方法
EP2841133A2 (fr) Dispositif de reconstitution
CZ298721B6 (cs) Bezpečnostní injekční zařízení pro kapalné nebo polotuhé přípravky
CN101765441A (zh) 包括再用防止机构的注射器组件
KR20170021017A (ko) 이중 주사기
US20250339619A1 (en) Auto-injector system
WO2024243553A2 (fr) Système auto-injecteur
EP3377148B1 (fr) Auto-injecteur
JP4790846B2 (ja) 注射装置
KR100895277B1 (ko) 약물 투여 장치
JPWO2021174143A5 (fr)
US20190125973A1 (en) Combination needleless hypodermic injector and cover sheet and related methods
US20150126969A1 (en) Drug delivery device and method
CN109310824A (zh) 药剂输送装置
WO2025226593A1 (fr) Auto-injecteur de suspension de particules

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24812010

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: AU2024274661

Country of ref document: AU